Carl Heneghan

Last updated

Carl Heneghan
Born (1968-01-23) January 23, 1968 (age 55)
UK
NationalityBritish
Known for epidemiology
Scientific career
Fields Medicine, epidemiology
Institutions University of Oxford, Kellogg College
Centre for Evidence-Based Medicine

Carl James Heneghan (born January 1968) is a British general practitioner physician, a clinical epidemiologist and a Fellow of Kellogg College. [1] [2] He is the director of the University of Oxford's Centre for Evidence-Based Medicine and former Editor-in-Chief of BMJ Evidence-Based Medicine. [3]

Contents

Heneghan is a Professor of Evidence-based medicine at the University of Oxford, NHS Urgent Care General Practitioner, and co-director of the Global Centre for Healthcare and Urbanisation. [4] Heneghan's work includes investigating the evidence for approval of drugs and devices, assessing health claims, and researching common presenting conditions in the community. [5] He has expertise in medical device regulations, diagnosis, screening and avoidable harms: including analyses of antiviral medication Tamiflu, acute respiratory infections and the transmission of SARs-CoV-2. [6] [7] [8]

Professor Heneghan is the Director of Programs in Evidence-Based Health Care at the University of Oxford, running since 2000 as the largest part time program in the Medical Sciences Division. [9] Heneghan writes regularly in the media, including at the Spectator and, along with Tom Jefferson, created the substack Trust the Evidence. [10] [11]

Career and research

Research

Heneghan is one of the founders of AllTrials, an international initiative which calls for all studies to be published, and their results reported. [12] He is a member of the Scientific Advisory Board of Collateral Global, an organisation that examines the global impact of the COVID-19 restrictions. [13] He has also been a clinical advisor to three UK All Parliamentary Party Groups, including on the use of surgical mesh, and has advised the World Health Organisation's clinical trials registry platform. [14] [15]

Honours and awards

In 2013, Heneghan was voted on to the Health Service Journal's list of top 100 most influential clinical leaders in England. [16] He was awarded NIHR Senior Investigation status in 2018. [17] Heneghan received a lifetime achievement award in 2019 from Oxford's Medical Science Division, for his sustained commitment to education and teaching. [18]

COVID-19 pandemic

On 21 September 2020, Heneghan alongside Sunetra Gupta, Karol Sikora and 28 signatories wrote an open letter to the UK prime minister, chancellor and chief medical officers asking for a rethink of the government's COVID-19 strategy. They argued in favour of a targeted approach to lockdowns advising that only over-65s and the vulnerable should be shielded. [19] [20]

During the pandemic, Heneghan has written for The Spectator magazine. In it, he has commentated on various aspects of the UK's governments response to the COVID-19 pandemic. On 19 November 2020, he wrote an article with Tom Jefferson, an epidemiologist, in which he criticised the science behind wearing face masks to reduce transmissions of COVID-19. [21] In the article he stated that; "Now we have properly rigorous scientific research that we can rely on, the evidence shows that wearing masks in the community does not significantly reduce the rates of infection." His claim was met with criticism. Sonia Sodha of The Guardian argued that Heneghan had made scientific errors because he had misrepresented a Danish randomized controlled trial which studied infection transmission rates on people who wore face masks. This was because the Danish mask study was only focused on infection transmissions for those wearing masks, rather than on the overall community, so could not be used to make judgements on the effects of face masks on community wide transmission rates. [22]

Kamran Abbasi, executive editor of the British Medical Journal (BMJ), also criticised Heneghan's claims about face masks because he believed his interpretation of the Danish study was inaccurate. However, Abbasi stressed that he believed it was wrong that Heneghan's opinion be marked as “false information" on Facebook because, as he wrote in the BMJ, "disagreement among experts, especially about interpretation of a study, is a common occurrence. It is the usual business of science." [23]

Publications

Related Research Articles

<span class="mw-page-title-main">Oseltamivir</span> Antiviral medication used against influenza A and influenza B

Oseltamivir, sold under the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B, viruses that cause the flu. Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection. They recommend it to prevent infection in those at high risk, but not the general population. The Centers for Disease Control and Prevention (CDC) recommends that clinicians use their discretion to treat those at lower risk who present within 48 hours of first symptoms of infection. It is taken by mouth, either as a pill or liquid.

Sir John Irving Bell is a Canadian-British immunologist and geneticist. From 2006 to 2011, he was President of the United Kingdom's Academy of Medical Sciences, and since 2002 he has held the Regius Chair of Medicine at the University of Oxford. He was since 2006 Chairman of the Office for Strategic Coordination of Health Research (OSCHR) but in 2020 became a normal member. Bell was selected to the Vaccine Taskforce sometime before 1 July 2020. Bell is also on the board of directors of the SOE quango Genomics England.

The National Institute for Health and Care Research (NIHR) is the British government’s major funder of clinical, public health, social care and translational research. With a budget of over £1.2 billion in 2020–21, its mission is to "improve the health and wealth of the nation through research". The NIHR was established in 2006 under the government's Best Research for Best Health strategy, and is funded by the Department of Health and Social Care. As a research funder and research partner of the NHS, public health and social care, the NIHR complements the work of the Medical Research Council. NIHR focuses on translational research, clinical research and applied health and social care research.

<span class="mw-page-title-main">Alimuddin Zumla</span> British-Zambian physician

Sir Alimuddin Zumla,, FRCP, FRCPath, FRSB is a British-Zambian professor of infectious diseases and international health at University College London Medical School. He specialises in infectious and tropical diseases, clinical immunology, and internal medicine, with a special interest in HIV/AIDS, respiratory infections, and diseases of poverty. He is known for his leadership of infectious/tropical diseases research and capacity development activities. He was awarded a Knighthood in the 2017 Queens Birthday Honours list for services to public health and protection from infectious disease. In 2012, he was awarded Zambia's highest civilian honour, the Order of the Grand Commander of Distinguished services - First Division. In 2023, for the sixth consecutive year, Zumla was recognised by Clarivate Analytics, Web of Science as one of the world's top 1% most cited researchers. In 2021 Sir Zumla was elected as Fellow of The World Academy of Sciences.

Tom Jefferson is a British epidemiologist, based in Rome, Italy, who works for the Cochrane Collaboration. Jefferson is an author and editor of the Cochrane Collaboration's acute respiratory infections group, as well as part of four other Cochrane groups. He was also an advisor to the Italian National Agency for Regional Health Services.

The Centre for Evidence-Based Medicine (CEBM), based in the Nuffield Department of Primary Care Health Sciences at the University of Oxford, is an academic-led centre dedicated to the practice, teaching, and dissemination of high quality evidence-based medicine to improve healthcare in everyday clinical practice. CEBM was founded by David Sackett in 1995. It was subsequently directed by Brian Haynes and Paul Glasziou. Since 2010 it has been led by Professor Carl Heneghan, a clinical epidemiologist and general practitioner.

<span class="mw-page-title-main">COVID-19</span> Contagious disease caused by SARS-CoV-2

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the virus SARS-CoV-2. The first known case was identified in Wuhan, China, in December 2019. The disease quickly spread worldwide, resulting in the COVID-19 pandemic.

<span class="mw-page-title-main">COVID-19 drug repurposing research</span> Drug repurposing research related to COVID-19

Drug repositioning is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.

<span class="mw-page-title-main">Face masks during the COVID-19 pandemic</span> Health control procedure against COVID-19

During the COVID-19 pandemic, face masks or coverings, including N95, FFP2, surgical, and cloth masks, have been employed as public and personal health control measures against the spread of SARS-CoV-2, the virus that causes COVID-19.

Sir Peter William Horby is a British physician, epidemiologist, Moh Family Foundation Professor of Emerging Infections and Global Health, and Director of the Pandemic Sciences Institute at the University of Oxford. He is the founder, and former director of the Oxford University Clinical Research Unit in Hanoi, Vietnam which was founded in 2006. In 2014, Horby established the Epidemic Research Group Oxford (ERGO). ERGO incorporates a number of international projects such as the European Commission funded PREPARE, the African coaLition for Epidemic Research, Response and Training (ALERRT), and the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC). Since 2016, Horby has been chair and executive director of ISARIC.

<span class="mw-page-title-main">RECOVERY Trial</span> Test of existing medicines on COVID-19

The Randomised Evaluation of COVID-19 Therapy is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. The trial was later expanded to Indonesia, Nepal and Vietnam. The trial has tested ten interventions on adults: eight repurposed drugs, one newly developed drug and convalescent plasma.

Marian Knight is a British physician who is a Professor of Maternal and Child Population Health at the University of Oxford. She is an Honorary Consultant of Public Health for Public Health England. During the COVID-19 pandemic Knight studied the characteristics and outcomes of pregnant women who tested positive for COVID-19.

<span class="mw-page-title-main">Transmission of COVID-19</span> Mechanisms that spread coronavirus disease 2019

The transmission of COVID-19 is the passing of coronavirus disease 2019 from person to person. COVID-19 is mainly transmitted when people breathe in air contaminated by droplets/aerosols and small airborne particles containing the virus. Infected people exhale those particles as they breathe, talk, cough, sneeze, or sing. Transmission is more likely the closer people are. However, infection can occur over longer distances, particularly indoors.

Azeem Majeed is a Professor and Head of the Department of Primary Care & Public Health at Imperial College, London, as well as a general practitioner in South London and a consultant in public health. In the most recent UK University Research Excellence Framework results, Imperial College London was the highest ranked university in the UK for the quality of research in the “Public Health, Health Services and Primary Care” unit of assessment.

Sir Andrew John Pollard is the Ashall Professor of Infection & Immunity at the University of Oxford and a Fellow of St Cross College, Oxford. He is an Honorary Consultant Paediatrician at John Radcliffe Hospital and the Director of the Oxford Vaccine Group. He is the Chief Investigator on the University of Oxford COVID-19 Vaccine trials and has led research on vaccines for many life-threatening infectious diseases including typhoid fever, Neisseria meningitidis, Haemophilus influenzae type b, streptococcus pneumoniae, pertussis, influenza, rabies, and Ebola.

Sir Martin Jonathan Landray is a British physician, epidemiologist and data scientist who serves as a Professor of Medicine & Epidemiology at the University of Oxford. Landray designs, conducts and analyses large-scale randomised control trials; including practice-changing international trials that have recruited over 100,000 individuals. Landray previously led the health informatics team that enabled the collection and management of data for the UK Biobank on over half a million people.

<span class="mw-page-title-main">UK COVID-19 Inquiry</span> Public inquiry into the United Kingdoms handling of COVID-19

The UK Covid-19 Inquiry is an ongoing, independent public inquiry into the United Kingdom's response to, and the impact of, the COVID-19 pandemic, and to learn lessons for the future. Public hearings began in June 2023. Boris Johnson announced the inquiry in May 2021, to start in Spring 2022. In December 2021, Heather Hallett was announced as the chair of the inquiry.

Eleanor Barnes is a British physician at the John Radcliffe Hospital and a Professor of Hepatology and Experimental Medicine at the University of Oxford. She has studied hepatitis C and the development of the development of HCV vaccines. She is a Fellow of the Academy of Medical Sciences and serves as the lead for hepatology at the National Institute for Health Research (NIHR) Clinical Research Network.

<span class="mw-page-title-main">Susanna Dunachie</span> British microbiologist

Susanna Jane Dunachie is a British microbiologist who is Professor of Infectious Diseases at the University of Oxford. Her work considers microbiology and immunology to better understand bacterial infection and accelerate the development of vaccines. She has focused on melioidosis, scrub typhus and tuberculosis. During the COVID-19 pandemic, she studied T cell immunity to severe acute respiratory syndrome coronavirus 2.

<span class="mw-page-title-main">PANORAMIC trial</span> Clinical trial of antivirals for COVID-19 infection

The Platform Adaptive Trial of Novel Antivirals for Early Treatment of COVID-19 in the Community is a clinical trial in the United Kingdom to test the effectiveness of new antiviral drugs at the early stages of COVID-19 infections. The study aims to find out if antivirals can prevent the need for hospitalisation and help faster recovery for people aged over 50 and those at higher risk due to underlying health conditions. PANORAMIC is sponsored by the University of Oxford and funded by the National Institute for Health and Care Research (NIHR). The trial was launched in December 2021, and as of June 2022, over 25,000 people are enrolled as participants.

References

  1. ↑ "Professor Carl Heneghan | University of Oxford". www.ox.ac.uk.
  2. ↑ "Carl Heneghan — Nuffield Department of Primary Care Health Sciences". www.phc.ox.ac.uk.
  3. ↑ "Editorial Board | BMJ Evidence-Based Medicine | BMJ Journals". BMJ Evidence-Based Medicine. Retrieved 9 September 2020.
  4. ↑ "Carl Heneghan". www.phc.ox.ac.uk. Retrieved 16 December 2023.
  5. ↑ "Carl Heneghan". www.phc.ox.ac.uk. Retrieved 16 December 2023.
  6. ↑ "heneghan and tamiflu - Search Results - PubMed". PubMed. Retrieved 16 December 2023.
  7. ↑ "heneghan and acute respiratory infections - Search Results - PubMed". PubMed. Retrieved 16 December 2023.
  8. ↑ "Transmission of SARS-CoV-2". www.cebm.ox.ac.uk. Retrieved 16 December 2023.
  9. ↑ "Carl Heneghan". www.phc.ox.ac.uk. Retrieved 16 December 2023.
  10. ↑ "Carl Heneghan, Author at The Spectator". The Spectator. 2 November 2023. Retrieved 16 December 2023.
  11. ↑ Heneghan, Carl (5 March 2023). "Trust the Evidence | Carl Heneghan | Substack". trusttheevidence.substack.com. Retrieved 16 December 2023.
  12. ↑ AllTrials. "About AllTrials". AllTrials. Retrieved 9 September 2020.
  13. ↑ "About Collateral Global". Collateral Global. Retrieved 22 December 2021.
  14. ↑ UK Parliament. "Surgical Mesh Volume Hansard 639: debated on Thursday 19 April 2018" . Retrieved 16 December 2023.
  15. ↑ "About ICTRP". www.who.int. Retrieved 16 December 2023.
  16. ↑ "Dr Carl Heneghan makes Top 100 Clinical Leaders List — Nuffield Department of Primary Care Health Sciences, University of Oxford" . Retrieved 9 September 2020.
  17. ↑ "NIHR Senior Investigators". www.spcr.nihr.ac.uk. Retrieved 16 December 2023.
  18. ↑ "Lifetime Achievement Award for Kellogg Fellow Carl Heneghan". Kellogg College. Retrieved 16 December 2023.
  19. ↑ Yorke, Harry (21 September 2020). "Reimposing national lockdown measures is 'increasingly unfeasible', leading scientists warn Boris Johnson". The Telegraph. ISSN   0307-1235 . Retrieved 11 December 2020.
  20. ↑ Boseley, Sarah (22 September 2020). "Covid UK: scientists at loggerheads over approach to new restrictions". The Guardian. ISSN   0261-3077 . Retrieved 27 September 2022.
  21. ↑ Heneghan, Jefferson, Carl, Tom (19 November 2020). "Landmark Danish study finds no significant effect for facemask wearers". www.spectator.co.uk. Archived from the original on 19 November 2020. Retrieved 13 December 2020.{{cite web}}: CS1 maint: multiple names: authors list (link)
  22. ↑ Sodha, Sonia (22 November 2020). "We need scientists to quiz Covid consensus, not act as agents of disinformation". The Guardian. Archived from the original on 22 November 2020. Retrieved 13 December 2020.
  23. ↑ Abbasi, Kamran (26 November 2020). "The curious case of the Danish mask study". BMJ. 371: m4586. doi: 10.1136/bmj.m4586 . ISSN   1756-1833.
  24. ↑ Heneghan, Carl. (2006). Evidence-based medicine toolkit. Badenoch, Douglas. (2nd ed.). Malden, Mass.: BMJ Books/Blackwell Pub. ISBN   978-1-4051-7236-3. OCLC   86074035.
  25. ↑ Perera, Rafael. (2008). Statistics toolkit. Heneghan, Carl., Badenoch, Douglas. Malden, Mass.: Blackwell. ISBN   978-1-4051-6142-8. OCLC   156816320.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.